Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Payables (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Payables data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Payables fell 56.94% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 56.94%, while the annual FY2025 figure was $2.3 million, 56.94% down from the prior year.
  • Payables reached $2.3 million in Q4 2025 per LCTX's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Payables topped out at $9.8 million in Q3 2022 and bottomed at $1.5 million in Q2 2025.
  • Average Payables over 5 years is $5.1 million, with a median of $5.0 million recorded in 2024.
  • Peak YoY movement for Payables: surged 219.26% in 2022, then crashed 75.22% in 2023.
  • A 5-year view of Payables shows it stood at $6.7 million in 2021, then increased by 28.38% to $8.6 million in 2022, then fell by 27.16% to $6.3 million in 2023, then decreased by 13.29% to $5.4 million in 2024, then plummeted by 56.94% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $2.3 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.